Peptides: The Science, Uses & Safety | Dr. Abud Bakri

Overview

Andrew Huberman and Dr. Abu Bakri explore the science, uses, and safety of peptides, categorizing them by receptor presence and discussing specific compounds like BPC-157, thymosin alpha-1, and GLP-1 agonists. They delve into BPC-157's potential for tissue repair and gut health, its lack of known receptors, and the regulatory challenges. The discussion also covers pinealon (EDR) for cognitive function and sleep, thymosin alpha-1 and beta-4 for immune support, GHK-Cu for skin rejuvenation, and GLP-1s for metabolic health, highlighting the need for more human data and physician-led research.

Key takeaways

BPC-157, a peptide derived from gastric juice, shows promise in animal studies for tissue repair and gut health but lacks identified receptors and extensive human data, leading to regulatory challenges.
Peptides like thymosin alpha-1 and beta-4, pinealon (EDR), and GHK-Cu are being explored for immune support, cognitive function, and skin rejuvenation, with varying levels of research and anecdotal evidence.
GLP-1 agonists (semaglutide, tirzepatide) represent a significant medical advancement for obesity and metabolic disorders, offering substantial weight loss but raising questions about long-term effects, dependency, and potential neurological impacts.
The 'trinity stack' (GLP-1s, GH secretagogues, androgens) is used for rapid physique transformation, but its long-term health consequences remain largely unknown.
The peptide market faces significant challenges in sourcing, quality control, and regulation, with physician-led access and clear nomenclature being crucial for safe and effective use.
Assessing immune health via lymphocyte-to-monocyte ratios on standard CBC tests offers a simple, overlooked metric for disease risk stratification.

Chapters

0:00 The 'Trinity Stack' for Rapid Fitness

Celebrities and CEOs use a 'trinity stack' of GLP-1 agonists, growth hormone modulators, and androgen modulation therapies (TRT).
This combination aims for rapid fat loss and muscle gain.
The health implications of this 'celebrity protocol' are still being investigated.

0:36 Introduction to the Huberman Lab Podcast and Guest

Andrew Huberman, a professor of neurobiology and ophthalmology at Stanford School of Medicine, hosts the podcast.
Guest Dr. Abu Bakri is an internal medicine physician knowledgeable about peptides.
The discussion will cover FDA-approved peptides (like GLP-1 agonists) and research peptides (like BPC-157).

1:41 Defining Peptides: Languages of the Body

Peptides are described as one of the body's communication languages, alongside steroid hormones.
They can be categorized by whether they have known receptors or not.
Peptides with strong clinical effects (e.g., GLP-1s) often have well-defined receptors.

8:16 BPC-157: Origin and Potential Mechanisms

BPC-157 is a 15-amino acid peptide derived from a larger 40 kDa protein found in gastric juice.
It was discovered by a Croatian research group in the 1990s.
Unlike some peptides, BPC-157's specific receptor is not yet identified.

8:53 Epigenetic Modifiers and Steroid Hormone Analogy

Some Russian peptides are described as epigenetic modifiers that bind to DNA grooves.
These modifiers can open or close chromatin, influencing gene expression.
This mechanism is compared to how steroid hormones bind to receptors to regulate gene transcription.

10:07 Categorizing Peptides: Known Receptors vs. Unknown

Peptides can be broadly categorized into those with known receptors (like GLP-1s) and those without.
Peptides without known receptors may still impact biology through other mechanisms.
Much of the data for peptides like BPC-157 comes from animal studies.

10:51 The Discovery and Early Research of BPC-157

BPC-157's discovery is linked to early 20th-century research on gastric juices for healing and stress adaptation.
Pavlov's work on gastric juices and Hans Selye's stress adaptation theory provided context.
The Croatian group isolated BPC-157 from gastric juice extracts, identifying its 15-amino acid sequence.

18:40 BPC-157's Effects in Animal Models

Studies involved inducing injuries in mice (tendon, ACL, burn wounds) and administering BPC-157 orally or via injection.
Observed effects included faster healing times for tendons and wounds.
Topical application prevented gastric ulcers in burn-injured mice, leading to its classification as an 'anti-stress' compound.

20:10 BPC-157's Potential Mechanisms of Action

BPC-157 appears to promote healing by modulating growth and healing pathways.
It increases VEGF signaling, promoting angiogenesis (blood vessel formation).
It can enhance cell migration, potentially when combined with TB-500.
It also exhibits anti-stress effects, counteracting the negative impact of corticosteroids on wound healing.

28:25 BPC-157 and Inflammation: A Nuance

BPC-157 doesn't necessarily lower inflammation but rather supports regenerative processes.
It helps 'call in' immune cells and healing factors, potentially by increasing growth hormone receptors on tendons.
It modulates nitric oxide synthesis, crucial for vasodilation and cell recruitment in wound healing.

30:11 Neurological and Psychiatric Effects of BPC-157 in Animals

Animal studies showed BPC-157 reduced intoxication effects from alcohol.
It also mitigated alcohol withdrawal symptoms in mice.
These effects suggest modulation of the gut-brain axis and potentially dopaminergic signaling.

31:40 Anecdotal Reports and BPC-157's Impact on Motivation

Some users report BPC-157 blunting the effects of ADHD medications like Adderall.
Anecdotal reports on Reddit mention anhedonia (lack of pleasure) and low energy.
These effects may relate to BPC-157's influence on dopaminergic and GABAergic pathways.

32:36 Safety and Adverse Events of BPC-157

Animal studies show very high doses (1000x therapeutic) of BPC-157 caused no adverse effects.
The LD50 (lethal dose for 50% of animals) is unknown, making FDA approval difficult.
The primary safety concern is the lack of extensive human clinical trial data.

34:09 Clinical Trials and Data Limitations for BPC-157

Two small trials (Phase 1 & 2) on rectal BPC-157 enemas for ulcerative colitis were conducted in Croatia.
Full data from these trials are not publicly available, only abstracts.
A key finding was that orally or rectally administered BPC-157 did not appear to become systemic, remaining localized to the gut lining.

37:13 Systemic vs. Localized Effects of BPC-157

Injectable BPC-157 is expected to go systemic.
Oral or rectal administration appears to stay localized to the gut, with no detectable levels in the blood in early trials.
A 2024 paper could detect BPC-157 administration for doping purposes, suggesting some systemic detection is possible.

38:43 Regulatory Status and Perceptions of BPC-157

BPC-157 is not FDA-approved and is legally available only for research purposes.
It was moved to Category 2 ('do not compound') by the FDA in late 2024, but 'PDA' (a form of BPC-157) is still prescribed.
There's skepticism regarding clinical trials conducted in Croatia compared to US-based research.

41:55 The Rise of Compounded and Gray Market Peptides

Shortages of GLP-1 drugs (Ozempic, Wegovy) led to a surge in compounded versions.
Compounding pharmacies were encouraged by the FDA to meet shortages but now face scrutiny.
The 'gray market' for research-use-only peptides has grown significantly, with raw materials often sourced from China.

57:32 Sourcing and Quality Control of Peptides

Active pharmaceutical ingredients (APIs) for most peptides, including semaglutide and tirzepatide, are sourced from China.
Compounding pharmacies vary in quality control; some have excellent testing, others do not.
Batch-to-batch consistency is a major concern for both compounded and research-grade peptides.

1:05:09 The 'Pet Peptide' Industry and Regulatory Ambiguity

The veterinary community is reportedly open to using peptides like testosterone and BPC-157 on pets.
The pet peptide industry is expected to grow significantly.
The regulatory status of oral BPC-157 (supplement vs. medication) remains unclear, with potential for it to appear on supplement websites.

1:09:04 Pinealon (EDR): Origin and Potential Effects

Pinealon (renamed EDR) is a tripeptide discovered by Soviet researcher Dr. Vladimir Kavsin.
It was developed to improve performance and combat aging effects in soldiers and astronauts.
It has no known receptor but is thought to act as an epigenetic modifier, influencing gene transcription.

1:18:22 Pinealon's Impact on REM Sleep and Cognitive Function

Andrew Huberman reports increased REM sleep and vivid dreams with pinealon, though Kavsin's original research did not mention REM sleep.
Pinealon is theorized to improve brain metabolism by modulating pathways like PPAR alpha/gamma.
Users report reduced brain fog and improved cognitive performance, with some taking it pre-workout.

1:27:34 Thymus Function and Involution

The thymus gland, crucial for T-cell development, shrinks significantly after puberty due to hormonal influences (androgens, estrogens, corticosteroids).
Residual thymus tissue in adults still plays a role in immune function.
Removal of thymus tissue during surgery has been linked to increased mortality from cancer and autoimmune diseases.

1:38:54 Thymosin Alpha-1 (Tα1) and Thymosin Beta-4 (TB-500)

Thymosin alpha-1 is FDA-approved (as Zadaxin) for children with primary T-cell deficiencies and used adjunctively for hepatitis B/C and cancers in some countries.
It enhances T-cell development and function, acting as 'jet fuel' for T-cells.
Thymosin beta-4 is a 43-amino acid peptide involved in actin cytoskeleton organization, aiding immune cell movement and wound repair; it's a known doping agent in horse racing.

1:42:15 GHK-Cu: Collagen Regulation and Aesthetic Uses

GHK-Cu is a tripeptide with a copper ion, found in type I collagen fibers.
Discovered by Dr. Lauren Pickart, it's believed to regulate collagen synthesis and breakdown.
Serum levels decrease significantly with age; topical application shows promise for skin rejuvenation and wound repair, and is used adjunctively with red light therapy.

1:51:42 GLP-1 Agonists: Transforming Metabolic Health

GLP-1 agonists (semaglutide, tirzepatide) are revolutionizing treatment for obesity, pre-diabetes, and diabetes.
They offer significant weight loss (10-30% body weight), unlike older drugs.
The long-term effects and necessity of lifelong use are still under investigation.

1:58:33 Potential CNS and Fertility Effects of GLP-1 Agonists

GLP-1 agonists may influence dopaminergic signaling, potentially reducing cravings for alcohol and other substances.
They can improve fertility in overweight/obese women by modulating leptin sensitivity.
Concerns exist about long-term effects on neuroplasticity and learning due to thousand-fold increases in GLP levels.

2:03:30 The 'Trinity Stack': Combining GLP-1s, GH, and Androgens

A popular 'trinity stack' combines GLP-1 agonists, growth hormone secretagogues, and androgen modulation therapies (like TRT).
This combination is used for rapid fat loss, muscle gain, and improved recovery.
The long-term health implications of this stack are not yet fully understood.

2:10:18 Growth Hormone Secretagogues (GHS) and Somatopause

GHS like MK-677 and tesamorelin stimulate the pituitary to release growth hormone (GH), addressing somatopause (age-related GH decline).
GH has benefits for skin, sleep, muscle recovery, and thymus regeneration.
Concerns include potential cancer promotion, insulin insensitivity, and increased prostate size.

2:20:45 The 'Wolverine Stack' and 'Glow Stack'

The 'Wolverine Stack' typically refers to BPC-157 and TB-500.
The 'Glow Stack' adds GHK-Cu to the mix, aiming for enhanced skin and collagen benefits.
There's debate about whether mixing peptides can cause denaturation.

2:35:07 Assessing Thymic Health and Lymphocyte Counts

Thymic size and function can be assessed via MRI, but a simpler indicator is the lymphocyte-to-monocyte ratio on a CBC.
A low ratio is associated with poorer outcomes in cardiovascular disease, cancer, and diabetes.
Most physicians are not aware of this metric's significance, highlighting a gap in standard medical education.

Summary, takeaways, and chapters were generated by AI from the video's transcript and may contain errors. The video belongs to its creator, Andrew Huberman.